(Q36407162)

English

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

7

object named as

Nyla A Heerema

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

10

object named as

Nita Seibel

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

James H. Feusner

3

object named as

James Feusner

0 references

Dorothy R. Barnard

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Beverly J Lange

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Franklin O Smith

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Patricia Dinndorf

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Stephen Feig

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Carola Arndt

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Robert J Arceci

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Margie Weiman

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Kathryn Dusenbery

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Kevin Shannon

13

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sandra Luna-Fineman

14

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Robert B Gerbing

15

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Todd A Alonzo

16

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

13 November 2007

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

111

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1044-1053

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Clinical implications of FLT3 mutations in pediatric AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Mortality in overweight and underweight children with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

30 September 2017

Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

28 June 2018

Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

28 June 2018

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2214754

21 September 2018

Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of chromosome abnormalities with patient characteristics, histologic subtype, and induction success in children with acute nonlymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal remission in childhood acute myeloid leukemia is an infrequent event

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of a derivative chromosome 17 by fish-technique

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized discontinuation design: application to cytostatic antineoplastic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous interleukin-2 infusion combined with cyclophosphamide- based combination chemotherapy in the treatment of hemato-oncological malignancies. Results of a phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/18000167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2007-04-084293

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36407162&oldid=1587302493"